IlmixGroup

IlmixGroup is a Russian pharmaceutical company founded in 2003, specializing in the development and manufacture of innovative drugs and supplements derived from natural compounds. The company focus is on reproductive health for both men and women, as well as the prevention and treatment of oncological conditions such as cervical dysplasia and benign breast diseases. In 2021, the company sold a portfolio of eight key brands, including Indinol Forto and Cervicon-DIM, to the Swiss pharmaceutical firm Acino. IlmixGroup continues to operate as a full-cycle pharmaceutical group, maintaining extensive manufacturing and R&D capabilities through its subsidiary, MiraxBioPharma, which provides contract manufacturing services for external partners.